1-4 of 4
Thomas Klag
Close
Sort by
Journal Articles

Weekend Drug Holiday of Dasatinib in CML Patients Not Tolerating Standard Dosing Regimens. Reducing Toxicity with Maintained Disease Control.

Paul La Rosee, MD, Armin Leitner, MD, Philippe Martiat, MD, Thomas Klag, MD, Samina Shazi, MD, Anne Treschl, MD, Martin C Müller, MD, Thomas Schenk, MD, Benjamin Hanfstein, Andreas Hochhaus, MD
Journal: Blood
Blood (2009) 114 (22): 1119.
https://doi.org/10.1182/blood.V114.22.1119.1119
Published: 2009
Journal Articles

Downregulation of the Common Cytokine Receptor Subunit Beta c by Omacetaxine in CML: A Potential Molecular Mechanism to Overcome Cytokine-Mediated Resistance against BCR-ABL-Inhibitors.

Thomas Klag, MD, Nicolai Härtel, MD, Thomas Schenk, MD, Adam R Craig, MD, PhD, Andreas Hochhaus, MD, Paul La Rosee, MD
Journal: Blood
Blood (2009) 114 (22): 3256.
https://doi.org/10.1182/blood.V114.22.3256.3256
Published: 2009
Journal Articles

Imatinib Treatment Induces Growth and Survival Promoting MAPK1/2 in Hematopoietic Cell Lines Expressing BCR-ABL T315I .

Nicolai Haertel, MD, Thomas Klag, Benjamin Hanfstein, MD, Martin C. Mueller, MD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD, Paul La Rosee, MD
Journal: Blood
Blood (2007) 110 (11): 3460.
https://doi.org/10.1182/blood.V110.11.3460.3460
Published: 2007
Journal Articles

MAPK-Activation in CD34+ CML Stem Cells Induced by Selective Abl-Inhibitors Is Not Observed Using the Combined Src/Abl-Inhibitor Dasatinib.

Paul La Rosee, MD, Nicolai Haertel, MD, Thomas Klag, Heiko Konig, MD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2007) 110 (11): 652.
https://doi.org/10.1182/blood.V110.11.652.652
Published: 2007